Different intravenous administration techniques for 5-fluorouracil: Pharmacokinetics and pharmacodynamic effects

Acta Oncologica

Volumn 35, Issue 2, 1996, Pages 207-212

  Larsson, Per Anders ^a,c   Carlsson, Göran ^a   Gustavsson, Bengt ^a   Graf, Wilhelm ^b   Glimelius, Bengt ^b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Östra Sjukhuest   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; COLORECTAL CANCER; CONJUNCTIVITIS; DIARRHEA; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; PRIORITY JOURNAL; RASH; STOMATITIS; VOMITING;

EID: 0029916516     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869609098503     Document Type: Article

References (25)

1. Heidelberger C. Fluorinated pyrimidines and their nucleosides. In Sartorelli AC, Johns DG, eds. Handbook of experimental pharmacology, antineoplastic and immunosuppressive agents. New York: Springer Verlag, 1975.
2. Moertel CG. Chemotherapy for colorectal cancer. Engl J Med 1994; 330: 1136-42.
3. Einhorn LH. Improvements in fluorouracil chemotherapy? J Clin Oncol 1989; 7: 1377-9.
4. Andersson M, Billström Å, Domellöf L, et al. Cardio-pulmonary elimination of 5-fluorouracil after bolus injection in the hepatic artery. Eur J Surg Oncol 1987; 13: 35-9.
5. Gustavsson BG, Brandberg Å, Regårdh CG, et al. Regional and systemic serum concentrations of 5-fluorouracil after portal and intravenous infusion: an experimental study in dogs. J Pharmacokinet Biopharm 1979; 7: 665-73.
6. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989; 16: 215-37.
7. Santini J, Milano G, Thyss A, et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 1989; 59: 287-90.
8. Port RE, Daniel B, Ding RW, et al. Relative importance of dose, body surface area, sex, and age of 5-fluorouracil clearance. Oncology 1991; 48: 177-81.
9. Grem JL. Fluorinated pyrimidines in cancer chemotherapy. In: Chabner BA, Collins JM, eds. Priniciples and practice. Philadelphia: J.B. Lippincott Company, 1990.
10. Anderson N, Lokich J. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration and cost comparisons. Cancer 1992; 70: 998-1002.
11. Chu E, Johnston P, Takimoto C, et al. Antimetabolites. Cancer Chemother Biol Response Modif 1993; 14: 1-25.
12. Aschele C, Sobrero A, Faderan MA, et al. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res 1992; 52: 1855-64.
13. Port RE. Edler L, Herrmann R, et al. Pharmacokinetics of 5-fluorouracil after short systemic infusion: plasma level at the end of the distribution phase as an indicator of the total area under the plasma concentration-time curve. Ther Drug Monit 1991; 13: 96-102.
14. Payet B, Fabre G, Tubiana N, et al. Plasma kinetic study of folinic acid and 5-methyltetrahydrofolate in healthy volunteers and cancer patients by high-performance liquid chromatogrraphy. Cancer Chemother Pharmacol 1987; 19: 319-25.
15. Heggie GD, Sommadossi J-P, Cross DS, et al. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987; 47: 2203-6.
16. van Groeningen CJ, Pinedo HM, Heddes J, et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res 1988; 48: 6956-61.
17. Yoshida T, Araki E, Iigo M, et al. Clinical significance of monitoring serum levels of 5-fluorouracil by continuous infusion in the patients with advanced colonic cancer. Cancer Chemother Pharmacol 1990; 26: 352-4.
18. Buckpitt AR, Boyd MR. A sensitive method for determination of 5-fluorouracil and 5-fluorodeoxyuridine in human plasma by high-pressure liquid chromatography. Anal Biochem 1980; 106: 432-7.
19. Gustavsson B, Baldesten A, Hasselgren P-O, et al. New assay of 5-fluorouracil in serum by isotachophoresis. Chromatogr 1979; 179: 151-9.
20. The Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Biochemical modulation of 5-fluorouracil: A randomized comparison of sequential methotrexate, 5-fluorouracil and leucovorin versus sequential 5-fluorouracil and leucovorin in patients with advanced symptomatic colorectal cancer. Ann Oncol 1993; 4: 235-40.
21. Glimenlius B, Hoffman K, Graf W, et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994; 73: 556-62.
22. Cao S, Rustum YM, Spector T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res 1994; 54: 1507-10.
23. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
24. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994; 12: 960-9.
25. Evans RM, Laskin JD, Hakala MT. Effects of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res 1981; 41: 3288-95.